Radium dichloride

Target Bone (bone metastases)Class Ion (calcium mimetic)Other names ²²³RaCl₂

15ongoing trials

1radiolabelled forms

1approved products

1,380publications (PubMed)

Structure

Structure not available in PubChem.

Properties (PubChem)

—

Radiolabelled forms

Form	Use	Molar mass (labelled form)	Ongoing trials	Most advanced phase	Approval
[²²³Ra]RaCl₂ Syntheses and QC ↗	Therapy	—	15	Phase 3	Xofigo US EU FR JP

Ongoing trials · 15Open in the radar →

Atlas trials whose studied drug or title names this vector, with this radionuclide.

Trial	Phase	Status	Sponsor	Countries
PEACE III · [223Ra]RaCl2 (Xofigo)NCT02194842 · Prostate – mCRPC	Phase 3	Active, not recruiting	European Organisation for Research and Treatment of Cancer - EORTC	12
[223Ra]RaCl2 (Xofigo)NCT03574571 · Prostate – mCRPC	Phase 3	Active, not recruiting	Memorial Sloan Kettering Cancer Center	4
ProBio · [223Ra]RaCl2 (Xofigo)NCT03903835 · Prostate – mCRPC	Phase 3	Recruiting	Karolinska Institutet	4
[223Ra]RaCl2 (Xofigo)NCT04071223 · Kidney	Phase 2	Active, not recruiting	National Cancer Institute (NCI)	1
[223Ra]RaCl2 (Xofigo)NCT04090398 · Breast	Phase 2	Active, not recruiting	National Cancer Institute (NCI)	1
[223Ra]RaCl2 (Xofigo)NCT04071236 · Prostate – mCRPC	Phase 2	Active, not recruiting	National Cancer Institute (NCI)	1
[223Ra]RaCl2 (Xofigo)NCT03317392 · Prostate – mCRPC	Phase 2	Active, not recruiting	National Cancer Institute (NCI)	1
BAT-RAD · [223Ra]RaCl2 (Xofigo)NCT04704505 · Prostate – mCRPC	Phase 2	Recruiting	Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins	2
[223Ra]RaCl2 (Xofigo)NCT03344211 · Prostate – mCRPC	Phase 2	Active, not recruiting	University of Southern California	1
[223Ra]RaCl2 (Xofigo)NCT03361735 · Prostate – hormone-sensitive	Phase 2	Active, not recruiting	City of Hope Medical Center	1
GUARD-QUANTUM · [223Ra]RaCl2 (Xofigo)NCT07717099 · Prostate – hormone-sensitive	Phase 2	Not yet recruiting	Alianza multidisciplinar para la investigación de los tumores genitourinarios -GUARD	1
AlphaBet · [177Lu]PSMA-I&TNCT05383079 · Prostate – mCRPC	Phase 2	Active, not recruiting	Peter MacCallum Cancer Centre, Australia	1
[223Ra]RaCl2 (Xofigo)NCT04206319 · Prostate – localised / recurrence	Phase 2	Active, not recruiting	National Cancer Institute (NCI)	1
[223Ra]RaCl2 (Xofigo)NCT05924672 · Prostate – mCRPC	Phase 2	Active, not recruiting	University of California, San Francisco	1
Rad2Nivo · [223Ra]RaCl2 (Xofigo)NCT04109729 · Prostate – mCRPC	Phase 1	Active, not recruiting	University of Utah	1

Published results · 1

2026-07

RADICAL (Alliance A031801) · negativeAdding radium to cabozantinib in kidney cancer with bone metastases brings no benefit: trial stopped for futility (16.7 vs 17.6 months).

J Clin Oncol ↗

PublicationsAll publications in PubMed ↗

1,380 publications in PubMed for the query below; the most recent:

"radium-223"[tiab] OR "radium 223"[tiab] OR "223Ra"[tiab]

Characterization of Adverse Drug Effects for Three Radiopharmaceuticals: A Descriptive Analysis from WHO-VigiAccess Cancer Biother Radiopharm, 2026
Radiopharmaceuticals and theranostics: reshaping cancer diagnosis and therapy with targeted radionuclides RSC Adv, 2026
Real-World Safety and Effectiveness of Radium-223 in Patients with Metastatic Castration-Resistant Prostate Cancer: Final Analysis of the RAPIT Study Target Oncol, 2026
Clinical translation of targeted alpha therapy: safety, dosimetry, radiation protection, and regulatory considerations Semin Nucl Med, 2026
Applicability of the defined solid angle method to the activity measurement of α-emitters for targeted radionuclide therapy Appl Radiat Isot, 2026
Bone Radiopharmaceuticals: Evolution from Palliative Therapy to Targeted Precision Oncology and Theranostics Biology (Basel), 2026
Bayesian re-analysis of ERA223 and PEACE-3 temporal dynamics and bone protection in radium-223-treated metastatic castration-resistant prostate cancer Jpn J Clin Oncol, 2026
'All-in-One' Micro- and Nanoscale MOFs for Combined Chemo-Radionuclide Therapy of Breast Cancer ACS Appl Bio Mater, 2026

Sources: PubChem and PubMed (NCBI), ClinicalTrials.gov and CTIS registries, approvals recorded by the atlas. PubChem data as of 28 October 2026.

Cite this page

Radium dichloride. Theranostic Atlas, LaRadiopharmacie.fr. Data as of 27 October 2026. https://theranosticatlas.com/molecule/radium-223/ (accessed [date]).

A monitoring tool with no regulatory value: check every item at its source.